Expertise in
18
conditions

Dr. Nicholas J. Vogelzang

Oncology
Comprehensive Cancer Centers Of Nevada
3730 S Eastern Ave, 
Las Vegas, NV 
Expertise in
18
conditions
Comprehensive Cancer Centers Of Nevada
3730 S Eastern Ave, 
Las Vegas, NV 

Overview

Nicholas Vogelzang is an Oncologist practicing medicine in Las Vegas, Nevada.

Dr. Vogelzang is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Orchiectomy, and Nephrectomy.

He is actively involved in clinical research, co-authoring 191 peer reviewed articles and participating in 22 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NV

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Comprehensive Cancer Centers of Nevada
3730 S Eastern Ave, Las Vegas, NV 89169

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Procedure, Other, Biological
Study Drugs: Pembrolizumab, Recombinant EphB4-HAS Fusion Protein
Study Phase: Phase 2
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Study Phase: Phase 2
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: SRF617, Etrumadenant, Zimberelimab
Study Phase: Phase 2
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drugs: TP-1454 Alone, TP-1454 Combination Therapy
Study Phase: Phase 1
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
View 9 Less Clinical Trials

189 Total Publications

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2025
Similar Doctors
Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Comprehensive Cancer Center Of Nevada

3730 S Eastern Ave, 
Las Vegas, NV 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Fadi Braiteh is an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Braiteh is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Agranulocytosis, Familial Colorectal Cancer, and Tissue Biopsy. Dr. Braiteh is currently accepting new patients.

Expertise in
61
conditions
Expertise in
61
conditions
Referral may be required

Comprehensive Cancer Centers Of Nevada

7445 Peak Dr, 
Las Vegas, NV 
 (9.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anu Thummala is an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Thummala is highly rated in 61 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Thummala is currently accepting new patients.

Expertise in
50
conditions
Expertise in
50
conditions
Referral required
Before you request

Comprehensive Cancer Centers Of Nevada

3730 S Eastern Ave, 
Las Vegas, NV 
 (0.1 miles away)
702-952-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Telehealth Visits are Available Edwin Kingsley, MD is a medical oncologist at Comprehensive Cancer Centers of Nevada (CCCN). He is board certified in internal medicine and medical oncology. Dr. Kingsley is an adjunct clinical professor at Touro University and has been teaching medical students for more than 14 years.My approach to patient care is to consider the entire patient, and not just his or her disease. I try to understand everything about the patient, their social, cultural, education, and family history, in addition to their medical history, and the disease for which they have been referred to me for treatment. This global approach to the patient gives me the proper and total context to help me deliver the very best care I can. Dr. Kingsley is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, and Lung Cancer. Dr. Kingsley is board certified in Internal Medicine (Sub: Medical Oncology) and Internal Medicine. Dr. Kingsley is currently accepting new patients.

Frequently Asked Questions about Dr. Nicholas J. Vogelzang

How do I make an appointment with Dr. Nicholas J. Vogelzang?

You can book an appointment with Dr. Nicholas J. Vogelzang by calling their office at 702-952-3400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nicholas J. Vogelzang a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nicholas J. Vogelzang is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nicholas J. Vogelzang specialize in?

While Dr. Nicholas J. Vogelzang is a Oncology, they have specific expertise in Prostate Cancer, Renal Cell Carcinoma (RCC), and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nicholas J. Vogelzang participate in research or clinical trials?

Yes. Dr. Nicholas J. Vogelzang has published 189 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Nicholas J. Vogelzang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nicholas J. Vogelzang accept my insurance?

Dr. Nicholas J. Vogelzang accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 702-952-3400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vogelzang's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 8 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile